BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Callejo A, Sedó-Cabezón L, Juan ID, Llorens J. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies. Toxics 2015;3:268-93. [PMID: 29051464 DOI: 10.3390/toxics3030268] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. Eur J Cancer 2017;87:75-83. [PMID: 29128692 DOI: 10.1016/j.ejca.2017.09.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
2 Paken J, Govender CD, Pillay M, Ayele BT, Sewram V. Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity. BMC Womens Health 2021;21:164. [PMID: 33879158 DOI: 10.1186/s12905-021-01313-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Carozzi VA, Cavaletti G. Toxicities of Therapeutic Agents Used in Medicine. Toxics 2016;4:E14. [PMID: 29051418 DOI: 10.3390/toxics4030014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Kayyali MN, Ramsey AJ, Higbee-Dempsey EM, Yan L, O'Malley BW Jr, Tsourkas A, Li D. The Development of a Nano-based Approach to Alleviate Cisplatin-Induced Ototoxicity. J Assoc Res Otolaryngol 2018;19:123-32. [PMID: 29349595 DOI: 10.1007/s10162-017-0648-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Paken J, Govender CD, Pillay M, Sewram V. A Review of Cisplatin-Associated Ototoxicity. Semin Hear 2019;40:108-21. [PMID: 31036989 DOI: 10.1055/s-0039-1684041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
6 Perše M. Cisplatin Mouse Models: Treatment, Toxicity and Translatability. Biomedicines 2021;9:1406. [PMID: 34680523 DOI: 10.3390/biomedicines9101406] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Prayuenyong P, Baguley DM, Kros CJ, Steyger PS. Preferential Cochleotoxicity of Cisplatin. Front Neurosci 2021;15:695268. [PMID: 34381329 DOI: 10.3389/fnins.2021.695268] [Reference Citation Analysis]
8 Callejo A, Durochat A, Bressieux S, Saleur A, Chabbert C, Domènech Juan I, Llorens J, Gaboyard-Niay S. Dose-dependent cochlear and vestibular toxicity of trans-tympanic cisplatin in the rat. Neurotoxicology 2017;60:1-9. [PMID: 28223157 DOI: 10.1016/j.neuro.2017.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
9 Theophanides T, Anastassopoulou J. The effects of metal ion contaminants on the double stranded DNA helix and diseases. Journal of Environmental Science and Health, Part A 2017;52:1030-40. [DOI: 10.1080/10934529.2017.1328950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen CH, Huang CY, Lin HH, Wang MC, Chang CY, Cheng YF. Association of Sodium Thiosulfate With Risk of Ototoxic Effects From Platinum-Based Chemotherapy: A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4:e2118895. [PMID: 34338793 DOI: 10.1001/jamanetworkopen.2021.18895] [Reference Citation Analysis]
11 Kros CJ, Steyger PS. Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies. Cold Spring Harb Perspect Med 2019;9:a033548. [PMID: 30559254 DOI: 10.1101/cshperspect.a033548] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
12 Kelly ML, Chu CC, Shi H, Ganser LR, Bogerd HP, Huynh K, Hou Y, Cullen BR, Al-Hashimi HM. Understanding the characteristics of nonspecific binding of drug-like compounds to canonical stem-loop RNAs and their implications for functional cellular assays. RNA 2021;27:12-26. [PMID: 33028652 DOI: 10.1261/rna.076257.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Paken J, Govender CD, Pillay M, Ayele BT, Sewram V. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa. BMC Cancer 2021;21:822. [PMID: 34271863 DOI: 10.1186/s12885-021-08567-0] [Reference Citation Analysis]
14 Perde-Schrepler M, Fischer-Fodor E, Virag P, Brie I, Cenariu M, Pop C, Valcan A, Gurzau E, Maniu A. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents. Hear Res 2020;388:107893. [PMID: 32006874 DOI: 10.1016/j.heares.2020.107893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Yin H, Zhang H, Kong Y, Wang C, Guo Y, Gao Y, Yuan L, Yang X, Chen J. Apelin protects auditory cells from cisplatin-induced toxicity in vitro by inhibiting ROS and apoptosis. Neuroscience Letters 2020;728:134948. [DOI: 10.1016/j.neulet.2020.134948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Gentilin E, Simoni E, Candito M, Cazzador D, Astolfi L. Cisplatin-Induced Ototoxicity: Updates on Molecular Targets. Trends in Molecular Medicine 2019;25:1123-32. [DOI: 10.1016/j.molmed.2019.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 14.0] [Reference Citation Analysis]
17 Lee CH, Lee DH, Lee SM, Kim ASY. Otoprotective Effects of Zingerone on Cisplatin-Induced Ototoxicity. Int J Mol Sci 2020;21:E3503. [PMID: 32429117 DOI: 10.3390/ijms21103503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
18 Sumiyoshi M, Soda H, Sadanaga N, Taniguchi H, Ikeda T, Maruta H, Dotsu Y, Ogawara D, Fukuda Y, Mukae H. Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum. Intern Med 2017;56:979-82. [PMID: 28420850 DOI: 10.2169/internalmedicine.56.7866] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
19 Fetoni AR, Paciello F, Troiani D. Cisplatin chemotherapy and cochlear damage: otoprotective and chemosensitization properties of polyphenols. Antioxid Redox Signal 2021. [PMID: 34731023 DOI: 10.1089/ars.2021.0183] [Reference Citation Analysis]
20 Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, Hauptmann M, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial. Otol Neurotol 2021;42:678-85. [PMID: 33710154 DOI: 10.1097/MAO.0000000000003069] [Reference Citation Analysis]
21 Naples JG, Ruckenstein MJ, Singh J, Cox BC, Li D. Intratympanic Diltiazem-Chitosan Hydrogel as an Otoprotectant Against Cisplatin-Induced Ototoxicity in a Mouse Model. Otol Neurotol 2020;41:115-22. [PMID: 31746818 DOI: 10.1097/MAO.0000000000002417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lustig LR. Diseases and targets for local drug delivery to the inner ear. Hear Res 2018;368:3-9. [PMID: 29778289 DOI: 10.1016/j.heares.2018.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
23 Budai B, Prekopp P, Noszek L, Kovács ER, Szőnyi M, Erdélyi DJ, Bíró K, Géczi L. GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs. J Mol Med (Berl) 2020;98:963-71. [PMID: 32435918 DOI: 10.1007/s00109-020-01921-y] [Reference Citation Analysis]
24 Youm I, West MB, Li W, Du X, Ewert DL, Kopke RD. siRNA-loaded biodegradable nanocarriers for therapeutic MAPK1 silencing against cisplatin-induced ototoxicity. Int J Pharm 2017;528:611-23. [PMID: 28627458 DOI: 10.1016/j.ijpharm.2017.06.035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
25 Pages BJ, Garbutcheon-singh KB, Aldrich-wright JR. Platinum Intercalators of DNA as Anticancer Agents: Platinum Intercalators of DNA as Anticancer Agents. Eur J Inorg Chem 2017;2017:1613-24. [DOI: 10.1002/ejic.201601204] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
26 Wang D, Shi S, Ren T, Zhang Y, Guo P, Wang J, Wang W. U0126 pretreatment inhibits cisplatin-induced apoptosis and autophagy in HEI-OC1 cells and cochlear hair cells. Toxicol Appl Pharmacol 2021;415:115447. [PMID: 33577918 DOI: 10.1016/j.taap.2021.115447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amable L, Cunningham LL. Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun 2017;8:1654. [PMID: 29162831 DOI: 10.1038/s41467-017-01837-1] [Cited by in Crossref: 121] [Cited by in F6Publishing: 114] [Article Influence: 30.3] [Reference Citation Analysis]
28 Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, Dolan ME. Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. Clin Cancer Res 2019;25:1147-55. [PMID: 30305294 DOI: 10.1158/1078-0432.CCR-18-2244] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 8.3] [Reference Citation Analysis]
29 Lee JH, Lee MY, Lim Y, Knowles J, Kim HW. Auditory disorders and future therapies with delivery systems. J Tissue Eng 2018;9:2041731418808455. [PMID: 30397431 DOI: 10.1177/2041731418808455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
30 Gao D, Yu H, Li B, Chen L, Li X, Gu W. Cisplatin Toxicology: The Role of Pro-inflammatory Cytokines and GABA Transporters in Cochlear Spiral Ganglion. CPD 2020;25:4820-6. [DOI: 10.2174/1381612825666191106143743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
31 Carneiro MC, Kimura TC, Tolentino ES, Pieralisi N, Veltrini VC. Unusual intraoral cancer with unexpected outcome in a patient with xeroderma pigmentosum: An alert for antineoplastic treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;129:e1-e11. [PMID: 31706804 DOI: 10.1016/j.oooo.2019.09.017] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-Associated Ototoxicity: A Review for the Health Professional. J Toxicol 2016;2016:1809394. [PMID: 28115933 DOI: 10.1155/2016/1809394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
33 Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, Chen Y, Zou Z. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm 2021;163:60-71. [PMID: 33775853 DOI: 10.1016/j.ejpb.2021.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wang W, Shanmugam MK, Xiang P, Yam TYA, Kumar V, Chew WS, Chang JK, Ali MZB, Reolo MJY, Peh YX, Karim SNBA, Tan AYY, Sanda T, Sethi G, Herr DR. Sphingosine 1-Phosphate Receptor 2 Induces Otoprotective Responses to Cisplatin Treatment. Cancers (Basel) 2020;12:E211. [PMID: 31952197 DOI: 10.3390/cancers12010211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
35 Viglietta V, Shi F, Hu QY, Ren Y, Keilty J, Wolff H, McCarthy R, Kropp J, Weber P, Soglia J. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. Invest New Drugs 2020;38:1463-71. [PMID: 32157599 DOI: 10.1007/s10637-020-00918-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
36 Steyger PS. Mechanisms of Aminoglycoside- and Cisplatin-Induced Ototoxicity. Am J Audiol 2021;30:887-900. [PMID: 34415784 DOI: 10.1044/2021_AJA-21-00006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhan T, Xiong H, Pang J, Zhang W, Ye Y, Liang Z, Huang X, He F, Jian B, He W, Gao Y, Min X, Zheng Y, Yang H. Modulation of NAD+ biosynthesis activates SIRT1 and resists cisplatin-induced ototoxicity. Toxicol Lett 2021;349:115-23. [PMID: 34089817 DOI: 10.1016/j.toxlet.2021.05.013] [Reference Citation Analysis]
38 Zhang W, Man R, Yu X, Yang H, Yang Q, Li J. Hydroxytyrosol enhances cisplatin-induced ototoxicity: Possible relation to the alteration in the activity of JNK and AIF pathways. Eur J Pharmacol 2020;887:173338. [PMID: 32781170 DOI: 10.1016/j.ejphar.2020.173338] [Reference Citation Analysis]
39 Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563-80. [PMID: 31092901 DOI: 10.1038/s41571-019-0218-0] [Cited by in Crossref: 343] [Cited by in F6Publishing: 349] [Article Influence: 171.5] [Reference Citation Analysis]
40 Hashemi-sheikhshabani S, Amini-farsani Z, Shamsara M, Sajadpoor Z, Sangtarash MH, Teimori H. Effect of valproic acid on cisplatin-resistant ovarian cancer cell lines. J Shahrekord Univ Med Sci 2019;21:39-44. [DOI: 10.34172/jsums.2019.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Fernandez K, Spielbauer KK, Rusheen A, Wang L, Baker TG, Eyles S, Cunningham LL. Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res 2020;389:107905. [PMID: 32062294 DOI: 10.1016/j.heares.2020.107905] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
42 Noszek L, Budai B, Prekopp P, Széchenyi R, Szőnyi M, Talpai S, Nagyiványi K, Bíró K, Géczi L. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy: Ototoxicity of Cisplatin in Germ Cell Tumor. The Laryngoscope 2017;127:E277-82. [DOI: 10.1002/lary.26325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
43 Gauvin DV, Yoder J, Zimmermann ZJ, Tapp R. Ototoxicity: The Radical Drum Beat and Rhythm of Cochlear Hair Cell Life and Death. Int J Toxicol 2018;37:195-206. [PMID: 29575954 DOI: 10.1177/1091581818761128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
44 Pages BJ, Sakoff J, Gilbert J, Rodger A, Chmel NP, Jones NC, Kelly SM, Ang DL, Aldrich-wright JR. Multifaceted Studies of the DNA Interactions and In Vitro Cytotoxicity of Anticancer Polyaromatic Platinum(II) Complexes. Chem Eur J 2016;22:8943-54. [DOI: 10.1002/chem.201601221] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
45 Peega T, Magwaza RN, Harmse L, Kotzé IA. Synthesis and evaluation of the anticancer activity of [Pt(diimine)(N,N-dibutyl-N'-acylthiourea)]+ complexes. Dalton Trans 2021;50:11742-62. [PMID: 34369524 DOI: 10.1039/d1dt01385h] [Reference Citation Analysis]
46 Wang X, Chen Y, Tao Y, Gao Y, Yu D, Wu H. A666-conjugated nanoparticles target prestin of outer hair cells preventing cisplatin-induced hearing loss. Int J Nanomedicine 2018;13:7517-31. [PMID: 30532536 DOI: 10.2147/IJN.S170130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
47 Esfahani Monfared Z, Khosravi A, Safavi Naini A, Radmand G, Khodadad K. Analysis of Cisplatin-Induced Ototoxicity Risk Factors in Iranian Patients with Solid Tumors: a Cohort, Prospective and Single Institute Study. Asian Pac J Cancer Prev 2017;18:753-8. [PMID: 28441710 DOI: 10.22034/APJCP.2017.18.3.753] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W. Metal Drugs and the Anticancer Immune Response. Chem Rev 2019;119:1519-624. [DOI: 10.1021/acs.chemrev.8b00396] [Cited by in Crossref: 108] [Cited by in F6Publishing: 91] [Article Influence: 36.0] [Reference Citation Analysis]
49 Qi J, Yao Q, Qian K, Tian L, Cheng Z, Wang Y. Gallium(III) complexes of α- N -heterocyclic piperidylthiosemicarbazones: Synthesis, structure-activity relationship, cellular uptake and activation of caspases-3/7/9. Journal of Inorganic Biochemistry 2018;186:42-50. [DOI: 10.1016/j.jinorgbio.2018.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
50 Shahab M, Rosati R, Meyer DN, Shields JN, Crofts E, Baker TR, Jamesdaniel S. Cisplatin-induced hair cell loss in zebrafish neuromasts is accompanied by protein nitration and Lmo4 degradation. Toxicol Appl Pharmacol 2021;410:115342. [PMID: 33245977 DOI: 10.1016/j.taap.2020.115342] [Reference Citation Analysis]
51 Waissbluth S, Del Valle Á, Chuang A, Becker A. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients. International Journal of Pediatric Otorhinolaryngology 2018;111:174-9. [DOI: 10.1016/j.ijporl.2018.06.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]